1 day-0.78%
1 week-14.38%
Current month-23.22%
1 month+25.25%
3 months+55.21%
6 months+7.20%
Current year-7.46%
1 week 5.06
Extreme 5.06
6.05
1 month 4.03
Extreme 4.0257
7.78
Current year 3.1
Extreme 3.1
7.78
1 year 3.1
Extreme 3.1
7.78
3 years 3.1
Extreme 3.1
31.2
5 years 3.1
Extreme 3.1
214.1
10 years 3.1
Extreme 3.1
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 15/05/2024
Chief Executive Officer 55 15/05/2024
Chief Operating Officer 61 15/05/2024
Director TitleAgeSince
Director/Board Member 64 01/12/2020
Director/Board Member 55 15/05/2024
Chairman 56 04/09/2024
Date Insider Type Main position Quantity % Market Cap. Importance
18/09/26 Sell

Chief Operating Officer

-6,850 0.3556%
18/09/26 Sell

Controller/Auditor

-4,077 0.2116%
18/09/26 Sell

Chief Executive Officer

-9,132 0.4741%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-14.38%+8.12%-73.23% 13.19M
+0.19%-3.96%+54.92%+69.15% 65.42B
-0.14%-3.20%+7.62%+89.74% 58.91B
+0.06%+0.15%+25.94%+87.89% 55.24B
-0.97%-3.91%+12.98%+113.88% 45.66B
-2.83%-7.58%+15.21%+22.34% 41.29B
+3.61%+2.63%+21.96%+46.39% 36.82B
-0.24%-9.59%+126.05%+647.44% 34.48B
+0.03%-0.93%+76.71%+57.74% 32.5B
+20.58%+22.35%-29.03%+482.03% 31.69B
Average +1.95%-1.79%+32.05%+154.34% 40B
Weighted average by Cap. +1.55%-0.98%+33.39%+154.15%
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in half-life-extended multispecific antibodies designed to deliver therapies. Through the proprietary INSPIRE platform, the Company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for efficacy and extended exposure. Its lead program, PRA-216, is a novel IL-4Ra/TSLP bispecific antibody in Phase II development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase II study planned in eosinophilic esophagitis. In addition to PRA-216, the Company is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need. Its second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. The Company is open to various partnering programs, including BDC-3042: P2-ready Dectin-2 Agonist mA, Preclinical CEA ISAC and Preclinical PD-L1 ISAC.
Employees
-
Date Price Change Volume
19/11/26 $5.060 -0.78% 35,623
18/11/26 $5.100 -9.73% 103,006
17/11/26 $5.650 -2.59% 86,791
16/11/26 $5.800 -4.61% 115,705
13/11/26 $6.080 +2.88% 28,118
  1. Stock Market
  2. Stocks
  3. BOLT Stock